Skip to main content
Caplight Logo









BlossomHill Therapeutics

BlossomHill Therapeutics

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://bhtherapeutics.com/

Last Round

Series B

Extension

Dec 10, 2025

Total Funding Raised

$343.65M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

BlossomHill Therapeutics is a biopharmaceutical company that discovers and develops small molecule medicines for the treatment of high-need cancers and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalsmall molecule therapeuticsoncologymacrocyclic chemistrydrug discoverynon-small cell lung cancerNSCLCEGFR-mutantKRAS inhibitorclinical trialsbiotechdrug pipelinecancer researchmedicinal chemistryclinical-stage

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BlossomHill Therapeutics Comparables

Compare BlossomHill Therapeutics with similar companies based on industry and business-model similarity.

BlossomHill Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
J INTS BIO
86%
Theseus Pharmaceuticals
82%
Kestrel Therapeutics
79%

BlossomHill Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionDec 10, 2025
Series BFeb 29, 2024
Series BDec 28, 2023
Series AMar 3, 2021

Key People

Founding team and executive leadership

J. Jean Cui

Scientific Founder, President and CEO

Founding Team

Jason Keyes

Chief Financial Officer

Executive Team

BlossomHill Therapeutics Investors

Notable investors and investment history

BlossomHill Therapeutics investors
InvestorRounds
BioTrack CapitalSeries B Extension
Janus Henderson GroupSeries B Extension
H&D Asset ManagementSeries B
Cormorant Asset ManagementSeries B, Series B Extension, Series A
OrbiMedSeries B, Series B Extension, Series A
Brahma CapitalSeries B Extension
Plaisance Capital ManagementSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors grew 65% MoM, reaching 4.5K.

  • Jun 30, 2026

    Grew 17% QoQ, from 59 to 69 employees.

Recent news

Latest coverage and updates

  • receives_financingAug 7, 2026

    BlossomHill Therapeutics, Inc. received financing of $150M in IPO on Jul 1st '26.

  • receives_financingAug 3, 2026

    BlossomHill Therapeutics, Inc. was planning to receive financing of $112M in IPO on Aug 3rd '26.

  • identified_as_competitor_ofAug 3, 2026

    BlossomHill Therapeutics, Inc. was planning to identify as competitor of AstraZeneca group on Aug 3rd '26.

  • goes_publicAug 3, 2026

    BlossomHill Therapeutics, Inc. went public on Aug 3rd '26.

  • goes_publicJul 20, 2026

    bhtherapeutics.com is planning to go public.

BlossomHill Therapeutics Filings

Explore SEC and related filing metadata, where available.

BlossomHill Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about BlossomHill Therapeutics's valuation, stock price, and market status.

Is BlossomHill Therapeutics a public or private company?

BlossomHill Therapeutics is a private company.

What is the current stock price of BlossomHill Therapeutics?

BlossomHill Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is BlossomHill Therapeutics worth (valuation)?

Valuation information for BlossomHill Therapeutics is not publicly available.

Can I buy BlossomHill Therapeutics stock?

BlossomHill Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was BlossomHill Therapeutics's last funding round?

BlossomHill Therapeutics's most recent funding round was Series B Extension on December 10, 2025.

Who are the main investors in BlossomHill Therapeutics?

Key investors in BlossomHill Therapeutics include BioTrack Capital, Janus Henderson Group, Brahma Capital, Colt Ventures, Cormorant Asset Management.

Will BlossomHill Therapeutics IPO soon?

No public IPO plans have been announced for BlossomHill Therapeutics.

How can I track BlossomHill Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor BlossomHill Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Diego, California
Employee Range51
Year Founded2020
Last FundingDec 10, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?